Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)
Close on Nov 18, 2026Market cap $1.67BP/E –Yield –
Braveheart Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$24.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$740.00K | – |
See a number that looks wrong?